Evolution of the tumor oxygenation and perfusion at the early stage of the treatment with SU5416, an inhibitor of Flk-1 tyrosine kinase.

R. Ansiaux, C. Baudelet, G. O.Cron, P. Martinive, J. De Wever, V. Gregoire, O. Feron, B. Gallez Biomedical Magnetic Resonance Unit, Catholic University of Louvain, Woluwe, Brussels, Belgium, Laboratory of Pharmacology and Therapeutics, Catholic University of Louvain, Woluwe, Brussels, Belgium, Laboratory of Molecular Imaging and Experimental Radiotherapy, Catholic University of Louvain, Woluwe, Brussels, Belgium